Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
Adding MabThera to first line chemotherapy significantlyincreases patients_ overall survival BASEL, Switzerland (21 May, 2007) _ In a study publishedyesterday in the Journal of Clinical Oncology, MabThera (rituximab)plus chemotherapy (MCP*) was shown to significantly improvesurvival in patients with follicular lymphoma (FL) compared tochemotherapy alone.1 Follicular lymphoma is the...MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
Data published today in the Journal of the National CancerInstitute BASEL, Switzerland, 2 May 2007 - In a study published today inthe Journal of the National Cancer Institute, the innovative cancerdrug MabThera was shown to improve overall survival in patientswith lymphoma regardless of the chemotherapy regimen used.1 Thereview further s...